SCHEMBL755503

SCHEMBL755503

Fc1ccc2nc(Cl)cn2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.46
CYP11B1 P15538 4/20 0.45
CYP11B2 P19099 4/20 0.45
ALDH1A3 P47895 4/20 0.41
MAP3K5 Q99683 1/20 0.39
CLK1 P49759 1/20 0.39
DYRK1A Q13627 1/20 0.39
RAB9A P51151 4/20 0.39
NPC1 O15118 3/20 0.39
GRM5 P41594 1/20 0.38
KDM4E B2RXH2 2/20 0.35
TP53 P04637 1/20 0.35
ALDH1A1 P00352 2/20 0.34
AHR P35869 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
CASP3 P42574 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SENP8 Q96LD8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7911725 0.78 RAB9A (0.60) APPALDH1A3RAB9ANPC1KDM4E
SCHEMBL2735660 0.77 NPC1 (0.55) APPALDH1A3MAP3K5RAB9ANPC1
SCHEMBL3485564 0.75 PIK3CG (0.60) APPCYP11B1CYP11B2ALDH1A3MAP3K5
SCHEMBL753772 0.75 PIK3CG (0.60) APPMAP3K5CLK1DYRK1ARAB9A
SCHEMBL16087132 0.75 APP (0.46) APPCYP11B1CYP11B2ALDH1A3MAP3K5
SCHEMBL12778738 0.75 APP (0.46) APPCYP11B1CYP11B2ALDH1A3MAP3K5
SCHEMBL14427902 0.75 CYP11B1 (0.57) APPCYP11B1CYP11B2ALDH1A3MAP3K5
SCHEMBL31732651 0.75 APP (0.50) APPCYP11B1CYP11B2ALDH1A3MAP3K5
SCHEMBL103426 0.75 GRM5 (0.47) APPCYP11B1CYP11B2ALDH1A3MAP3K5
SCHEMBL3340576 0.75 SMN1; SMN2 (0.54) DYRK1ARAB9ANPC1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2757882-B1 IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS MERCK SHARP & DOHME (US) 2020-11-04 EP disclosed
EP-2757882-B1 IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS MERCK SHARP & DOHME (US) 2020-11-04 EP disclosed
US-9518055-B2 Imidazopyridyl compounds as aldosterone synthase inhibitors MERCK SHARP & DOHME (US) 2016-12-13 US disclosed
US-9518055-B2 Imidazopyridyl compounds as aldosterone synthase inhibitors MERCK SHARP & DOHME (US) 2016-12-13 US disclosed
US-9518055-B2 Imidazopyridyl compounds as aldosterone synthase inhibitors MERCK SHARP & DOHME (US) 2016-12-13 US disclosed
US-20160031882-A1 IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS MERCK SHARP & DOHME LLC 2016-02-04 US disclosed
US-20160031882-A1 IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS MERCK SHARP & DOHME LLC 2016-02-04 US disclosed
US-20160031882-A1 IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS MERCK SHARP & DOHME LLC 2016-02-04 US disclosed
US-9173873-B2 2015-11-03 US disclosed
US-9173873-B2 2015-11-03 US disclosed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed
US-20140235667-A1 IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS MERCK SHARP & DOHME CORP. 2014-08-21 US disclosed
US-20140235667-A1 IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS MERCK SHARP & DOHME CORP. 2014-08-21 US disclosed
US-20140235667-A1 IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS MERCK SHARP & DOHME CORP. 2014-08-21 US disclosed
EP-2757882-A1 IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2014-07-30 EP disclosed
WO-2013043518-A1 IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-03-28 WO disclosed
WO-2013043518-A1 IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-03-28 WO disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP disclosed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235667-A1 IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS NR3C2, CYP21A2, HSD11B1 APP 3230/4885CYP11B1 4/4885CYP11B2 6/4885
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD APP 4224/4885CYP11B1 1090/4885CYP11B2 1479/4885
US-20160031882-A1 IMIDAZOPYRIDYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS NR3C2, CYP21A2, HSD11B1 APP 3271/4885CYP11B1 4/4885CYP11B2 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.